Compare SYM & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SYM | COGT |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.5B |
| IPO Year | 2021 | 2018 |
| Metric | SYM | COGT |
|---|---|---|
| Price | $34.25 | $27.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 12 |
| Target Price | ★ $59.84 | $55.82 |
| AVG Volume (30 Days) | 1.6M | ★ 2.0M |
| Earning Date | 11-23-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $2,246,922,000.00 | $7,871,000.00 |
| Revenue This Year | $24.54 | N/A |
| Revenue Next Year | $28.88 | $5,819.52 |
| P/E Ratio | $292.54 | ★ N/A |
| Revenue Growth | ★ 25.65 | N/A |
| 52 Week Low | $33.17 | $27.74 |
| 52 Week High | $87.88 | $43.73 |
| Indicator | SYM | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 34.83 | 37.79 |
| Support Level | $33.17 | N/A |
| Resistance Level | $44.66 | $37.34 |
| Average True Range (ATR) | 2.09 | 1.81 |
| MACD | -0.19 | -0.30 |
| Stochastic Oscillator | 16.36 | 4.41 |
Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.